title: BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
abstract: The identification of cancer susceptibility genes offers new avenues for selecting high-risk individuals as subjects for chemoprevention trials. Because carriers of predisposing mutations are at high risk, they are more likely to enroll and comply with chemoprevention trials, and meaningful results can be achieved with smaller numbers of participants and shorter periods of follow-up. Such studies have immediate benefits for carriers themselves, but they are also likely to result in effective chemopreventive strategies for the general population. In this review, we discuss BRCA1 and BRCA2 carriers as potential candidates for breast and ovarian cancer chemoprevention trials. The existence of a large population with a high frequency of easily identifiable BRCA1/2 mutations can provide ample opportunity for such studies. However, the possibility that tumor characteristics and hormonal profile of BRCA1/BRCA2 related cancers are not completely equivalent to cancers in the general population should be borne in mind.
authors.affiliation: Medical Genetics Unit, Shaare Zedek Medical Center, Hebrew University Hadassah Medical School, Jerusalem, Israel. amnonl@cc.huji.ac.il
authors.forename: E
authors.initials: E
authors.lastname: Levy-Lahad
authors.forename: M
authors.initials: M
authors.lastname: Krieger
authors.forename: O
authors.initials: O
authors.lastname: Gottfeld
authors.forename: P
authors.initials: P
authors.lastname: Renbaum
authors.forename: G
authors.initials: G
authors.lastname: Klein
authors.forename: S
authors.initials: S
authors.lastname: Eisenberg
authors.forename: A
authors.initials: A
authors.lastname: Lahad
authors.forename: B
authors.initials: B
authors.lastname: Kaufman
authors.forename: R
authors.initials: R
authors.lastname: Catane
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D005260:Female; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D007585:Jews / Q000235:genetics; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D013629:Tamoxifen / Q000627:therapeutic use; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D016588:Anticarcinogenic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors; D013629:Tamoxifen